Riggs B L, Seeman E, Hodgson S F, Taves D R, O'Fallon W M
N Engl J Med. 1982 Feb 25;306(8):446-50. doi: 10.1056/NEJM198202253060802.
We assessed the rates of vertebral fracture in patients with postmenopausal osteoporosis. Forty-five patients were not treated (91 person-years of observation); 59 were treated conventionally, with calcium (alone or combined with estrogen) or vitamin D or both (218 years); and 61 were treated with sodium fluoride combined with conventional therapy (251 years). The fracture rate (per thousand person-years) was 834 in untreated patients, 419 in those given calcium with or without vitamin D, 304 in those given fluoride and calcium with or without vitamin D, 181 in those given estrogen and calcium with or without vitamin D, and 53 in those given fluoride, estrogen, and calcium with or without vitamin D. It was reduced in all treatment groups (P less than 0.001 for calcium and P less than 1 x 10(-6) for other combinations); fluoride (one years of treatment) and estrogen (but not vitamin D) independently reduced the rate from that observed with calcium alone (P less than 0.001). The combination of calcium fluoride, and estrogen was more effective than any other combination (P less than 0.001). These results provide grounds for optimism about the efficacy of combinations of available agents with sodium fluoride for fracture in postmenopausal osteoporosis.
我们评估了绝经后骨质疏松症患者的椎体骨折发生率。45例患者未接受治疗(观察91人年);59例接受常规治疗,使用钙(单独或与雌激素联合)或维生素D或两者(218人年);61例接受氟化钠联合常规治疗(251人年)。未治疗患者的骨折发生率(每千人年)为834,给予钙(无论是否使用维生素D)的患者为419,给予氟化物和钙(无论是否使用维生素D)的患者为304,给予雌激素和钙(无论是否使用维生素D)的患者为181,给予氟化物、雌激素和钙(无论是否使用维生素D)的患者为53。所有。所有治疗组的骨折发生率均降低(钙治疗组P<0.001,其他联合治疗组P<1×10⁻⁶);氟化物(治疗1年)和雌激素(而非维生素D)独立于单独使用钙时观察到的发生率降低骨折发生率(P<0.001)。氟化钙和雌激素的联合治疗比其他任何联合治疗更有效(P<0.001)。这些结果为使用氟化钠联合现有药物治疗绝经后骨质疏松症骨折的疗效提供了乐观依据。